| Similar Articles |
|---|
 |
Inc.
July 2005
Jim Melloan |
Mr. Cashman, You're On Chris Cashman is looking for $500,000. He has 45 minutes to convince the skeptics at Robin Hood Ventures that he's a good investment.   |
Inc.
December 2006 |
Updates Making a Turnaround... The Cash Keeps On Coming... |
The Motley Fool
June 6, 2008
Brian Lawler |
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them. |
The Motley Fool
August 26, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of future investments: antibiotic developer Protez Pharmaceuticals... voice and data networking equipment maker Alloptic... VC fundraising news... |
The Motley Fool
April 22, 2008
Brian Lawler |
No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year. |
The Motley Fool
October 23, 2006
Brian Lawler |
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock. |
| AskMen.com |
Robin Hood Arrested Authorities said a 34-year-old named Robin Joshua Hood found someone's wallet in downtown Denver and apparently began using the man's name in a ploy to avoid being caught on a warrant. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
The Motley Fool
April 25, 2007
Brian Lawler |
Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note. |
The Motley Fool
November 6, 2006
Brian Gorman |
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note. |
Bio-IT World
November 2005
Mark D. Uehling |
The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry. |
The Motley Fool
April 21, 2005
Stephen D. Simpson |
Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space. |
The Motley Fool
October 23, 2009
Brian Orelli |
Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own. |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
The Motley Fool
October 22, 2007
Brian Lawler |
No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note. |
The Motley Fool
February 3, 2006
W.D. Crotty |
Red Robin's Feathers Ruffled The upscale burger chain reports an SEC investigation and a California lawsuit. Investors, take note. |
The Motley Fool
March 16, 2005
Cliff Malings |
Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition. |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. |
The Motley Fool
March 29, 2006
Stephen D. Simpson |
Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note. |
The Motley Fool
September 1, 2005
Stephen D. Simpson |
Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note. |
